We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for solid and hematological tumors. Our platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells. We are one of the most advanced gamma-delta T cell companies and were the first to bring genetically modified gamma-delta T cells into the clinic. We are utilizing our suite of DeltEx™ platform technologies to achieve our mission of what we refer to as CANCER ZERO ─ the elimination of all cancer cells in every patient battling the disease. We believe this aspiration will one day be achievable and that it is our responsibility to advance next-generation cancer treatments for patients in need.

Our lead product candidates are clinical stage assets. INB-400 is currently in a Phase 2 clinical trial for the treatment of newly diagnosed glioblastoma or GBM while the Phase 1, INB-200, also in newly diagnosed GBM is nearing completion. INB-100 is in a Phase 1 clinical trial for the treatment of patients with leukemia that are undergoing hematopoietic bone marrow transplantation. Our platform has also yielded a broad portfolio of preclinical and discovery-stage programs focused on addressing solid tumors.